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USE OF pH AND TEMPERATURE SENSITIVE NANOSPHERES IN 
CARTILAGE TISSUE ENGINEERING 
SUMMARY 
The developments in science and technology prolong the life span of the human 
beings. Long life brings with it problems associated with degenerative diseases and 
worn out organs. Tissue engineering aims at repairing diseased or nonfunctional 
organs through the design and use of cell carrying biodegradable biomaterials. The 
cell sources available for cartilage tissue engineering are mainly chondrocytes and 
mesenchymal stem cells. Upon use of appropriate growth factors mesenchymal stem 
cells are known to differentiate into a variety of cells such as bone, cartilage, fat and 
muscle cells.  
In this study, the aim is to obtain cartilage regeneration through differentiation of 
mesenchymal stem cells. The growth factor choice is crucial for a successful result. 
During the damage and repair of joint cartilage a variety of growth factors such as 
insulin-like growth factor I (IGF-I), and transforming growth factor beta1 (TGF-β1) 
are released. Knowing that introduction of TGF-β1 on chondrocytes increases cell 
proliferation and IGF-I induces chondrocyte phenotype in 3D in vitro cultures, both 
growth factors are studied for their effect as controlled release formulation 
Controlled release of IGF-I and TGF-β1 were realized from two different polymeric 
nanospheres, namely PLGA and NIPAM. The nanospheres were introduced to 
PLGA based cell carriers and the effect of their release profile on cell proliferation 
and differentiation was studied. At the end of the experiments, it can be concluded 
that cells treated with IGF-I and IGF-I / TGF-β1 containing nanospheres give the 
best results with respect to cartilage differentiation onto scaffolds. It thus appears 
that, usage of growth factor loaded nanospheres could have a serious contribution to 
cartilage tissue engineering. 
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 pH VE SICAKLIĞA DUYARLI NANOKÜRELERİN KIKIRDAK DOKU 
MÜHENDİSLİĞİNDE KULLANIMI 
ÖZET 
Bilim ve teknolojideki gelişmeler insanların yaşam süresini uzatmaktadır. Uzun 
yaşam beraberinde dejeneratif hastalıklar ve yıpranan organlarla ilgili sorunları 
getirmektedir. Doku mühendisliği hasar görmüş ya da fonksiyonlarını yitirmiş 
organların tedavisi amacıyla hücre taşıyan biyobozunur malzemelerin tasarımlarını 
ve uygulanmalarını hedeflemektedir.  
Kıkırdak doku mühendisliğinde kullanılabilecek hücre kaynakları temelde 
kondrositler ve mezenşimal kök hücreleridir. Uygun büyüme faktörleri 
kullanıldığında, mezenşimal kök hücreleri kemik, kıkırdak, yağ ve kas gibi değişik 
dokulara dönüşebilmektedir. Bu çalışmada mezenşimal kök hücrelerin kıkırdak 
hücrelerinin kondrositlere dönüşmesi ve kıkırdak rejenerasyonunu başlatması 
sağlanmaya çalışılmıştır. Bu aşamada büyüme faktörlerinin tipi büyük önem 
taşımaktadır. Eklem kıkırdağının hasarlanması ve onarılması sırasında Insülin 
Benzeri Büyüme Faktörü - I (IGF-I), ve Transforming Büyüme Faktörü Beta1 
(TGF-1) gibi bir çok büyüme faktörü salınmaktadır. Kıkırdak hücreleri üzerine 
TGF-1 eklenmesi kondrosit çoğalmasını teşvik etmekte, IGF-I ise 3 boyutlu in 
vitro kültürlerde kondrosit fenotipini artırmaktadır. 
Bu çalışmada bu iki büyüme faktörü ve hücreler ayrı ayrı PLGA temelli akıllı 
(responsif) hücre taşıyıcılar içine yüklenmiş ve pH ile sıcaklığa bağlı olarak birbirini 
izleyen zamanlarda salımları sağlanarak hücrelerin çoğalması ve farklılaşması 
sağlanmıştır. Yapılan deneyler sonunda IP ve IPTN ile birlikte bulunan hücrelerin, 
iskelet yapılar üzerinde kıkırdak farklılaşması açısından en iyi sonuçları verdiği 
gözlemlenmiştir. Böylece, büyüme faktörü yüklü nanokürelerin kıkırdak doku 
mühendisliğinde ciddi katkıları olabileceği görülebilmektedir. 
 
xxii 
 
 
 
1 
 
1. INTRODUCTION 
1.1. Articular Cartilage 
Articular cartilage essentially provides mechanical support for the functioning of 
diarthrodial joints that are found between bones. In a living joint, cartilage can 
hold up against a great pressure which can be up to 20- fold body weight, 
therefore, it specifically functions in avoiding the possible subchondral bone 
damages (Plumb and Aspden et al., 2005; Li et al., 2008). In comparison with bone 
and muscle, cartilage is known to show lower metabolic activity and limited 
damage healing. Its macroscopic surface properties include smoothness, glistening 
and tough material appearance. Furthermore, cartilage is composed of mostly 
extracellular matrix (ECM) and does not include any blood and lymph vessels or 
nerve ends. Moreover, endoplasmic reticulum and golgi apparatus are the most 
distinguishable organelles of the cartilage cell with the light microscope and many 
of them contain lipid and glycogen stocks, and also vesicles functioning in 
secretion (Dedivitis et al., 2004; Temenoff et al., 2000). 
The non-homogenous tissue characteristic of articular cartilage comes from the 
fact that in humans, cartilage cells, known as chondrocytes, represent only about 
1% of the volume of hyaline cartilage. In spite of their small volume, chondrocytes 
are essential in replacing degraded matrix molecules so that tissue can maintain its 
usual size and mechanical abilities (Darling et al., 2005; Temenoff et al., 2000). 
Additionally, secretion and maintaining of ECM that have a part in growth, 
mechanical support and the function of diarthrodial joints, are among the specific 
functions of chondrocytes (Yang et al., 2005). 
Cartilage, located between joint cavities to subchondral bone, can be divided in 4 
zones: superficial, middle, deep and calcified (Figure 1.1). The superficial zone 
consists of two distinct layers. First layer is described as the cover of the joint and 
it consists of a sheet composed of predominantly collagen fibers with a little 
polysaccharide content without any cells. Under this sheet, chondrocytes can be 
2 
 
found layered in a flattened and parallel manner to the surface that constitutes the 
second layer. The collagen fibrils are also arranged parallel to the articular surface 
in this zone.  
In the middle zone (or transitional), round chondrocytes are surrounded by a 
narrow pericellular region of low collagen fibril content (Temenoff et al., 2000; 
Poole et al., 2001). This zone consists of the highest level of proteoglycan and it 
has a random arrangement of collagen. 
 
Figure 1.1. Schematic representation of articular cartilage (Mow and Ratcliffe, 1997) 
The deep zone has the lowest cell density, but it shows maximal aggrecan content, 
also consists of large and spherical cells clustered in column. Columns of 
chondrocytes can be observed as arrayed along the axis of fibril orientation, and 
additionally, collagen fibrils are oriented in a vertical pattern, perpendicular to the 
bone (Mow and Ratcliffe., 1997). 
The calcified zone is partly mineralized and lies closest to the subchondral bone. It 
acts as a transition between cartilage and the underlying subchondral bone. As a 
consequence of being the interface between the soft cartilage and much harder 
bone, significant shear stress can be produced in this calcified zone. The local 
chondrocytes of this zone are smaller; they have almost no endoplasmic reticulum 
and structurally seem to be surrounded by calcified ECM, therefore having almost 
no space for metabolic activities (Cohen et al., 1998; Temenoff et al., 2000). 
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1.2. Molecular Components of Articular Cartilage 
ECM consists of collagens, proteoglycans, and non-collagenous proteins (DiCesare 
et al., 1995). The primary structure of a collagen molecule is a long and tight 
triple-stranded helix, in which three collagen polypeptide chains, [α1(II)]3 (α 
chains), are tied around one another (Alberts et al., 2002). In macromolecular 
framework, collagens (especially type II) are responsible in the physical 
entrapment of the other macromolecules and in creating tensile strength against 
stretching. While proteoglycans, composed of about 95% polysaccharide and 5% 
protein, provide some physical properties to the tissue. Finally, non-collagenous 
proteins affect the stabilization of the ECM matrix and help building interactions 
between chondrocytes and matrix.  
In addition to abundantly found type II collagens (85-90% of the total collagen 
content), collagen types VI, IX, X and XI are found in articular cartilage. Differing 
from other type of collagens, type II collagen is highly responsible for interaction 
with water since it consists of a high amount of bound carbohydrate groups. 
Collagen type VI is a glycoprotein with a short collagenous central domain. Being 
5 nm in diameter, its supramolecular structure has 100 nm periodicity (Meyer and 
Wiesmann, 2006). Types IX and XI together with type II create fibrils that twine 
together to form a meshed structure which provides the tensile strength, and also 
physical entrapment of the other macromolecules (Temenoff et al., 2000). 
Collagen type IX is found on the external part of the collagen fibrils, allowing the 
fibrils to interact with proteoglycan macromolecules, which stabilizes the meshed 
structure. It is a member of subfamily of collagens, FACIT (Fibril Associated 
Collagens with Interrupted Triplehelices), and has a molecular weight of 222 kDa. 
Collagen types IX and XI constitute 3-10% of the collagen content, depending on 
age and the source of cartilage. Collagen type X is located in the calcified area of 
articular cartilage (Ackermann and Steinmeyer, 2005). There are two types of 
collagen fibrils: thin (16-nm diameter) and thick (~40-nm diameter). The cores of 
thin fibrils are particularly composed of collagen type XI (Figure 1.2), a fibrillar 
collagen type with 545 kDa weight (Meyer and Wiesmann, 2006; Kadler et al., 
2008). 
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Figure 1.2. Microfibril structure of a thin collagen fibril (Blue: collagen II 
molecules; yellow: collagen XI molecules; red: collagen IX 
molecules). A pair of collagen XI microfibrils comprises half of a 4 
microfibril core surrounded by 10 microfibrils at the surface. The 
collagen XI/IX/II assembly is a crosslinked heteropolymer (Kadler et 
al., 2008).  
Predominant collagen of cartilage and intervertebral disc is collagen type II that 
provides tensile strength and enables the tissue to resist shearing forces (Meyer and 
Wiesmann, 2006). Being a triple helical glycoprotein with a molecular weight of 
425 kDa, collagen type II possesses a fibrillar structure with 67 nm periodicy. 
Collagen type II is produced and then secreted by chondrocytes by exocytosis, 
supporting chondrocyte adhesion and phenotypic differentiation of cells. It 
contains specifically proline and lysine amino acids and many modifications that 
are almost unique to collagen. These modifications such as hydroxylation of 
residues are introduced during biosynthesis eventually creating hydroxyproline and 
hydroxylysine (Stryer, 1981). The high hydroxylysine content of collagen type II,  
facilitates glycosylation (a property of hydrophilic tissue), makes collagen type II 
the most suitable component of cartilage (Ackermann and Steinmeyer, 2005). The 
abundance and structures of collagen molecules vary according to the anatomy and 
age of the person (Meyer and Wiesmann, 2006).   
Aggrecan, a non-collagenous protein with 87% chondroitin sulphate (CS) and 6% 
keratan sulfate (KS) side chains, is another essential component of cartilage tissue 
(Figure 1.3). It is a large proteoglycan having a molecular weight of 205 kDa, and 
consists of three globular domains (G1, G2, G3) with glycosaminoglycan (GAG) 
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attachment regions for KS an CS. Forming complexes with hyaluronan through G1 
domain, it belongs to the family of aggregating proteoglycans, hence the name is 
“aggrecan” (Gomes et al., 2004). The large aggregates formed by aggrecan and 
hyaluronan (>200 MDa) provide the maintenance of aggrecan within the ECM 
(Figure 1.4). Due to the presence of large number of negatively charged side 
groups, it provides resistance to compression. The primary role of aggrecan is to 
swell and hydrate collagen framework, making high osmotic pressure in order to 
reinforce cartilage. Studies have shown that aggrecan coats collagen type II, 
preventing it from proteolytic degradation. Without aggrecan molecules, collagen 
fibers are not supported well, thus the tissue is open to damaging forces (Pratta et 
al., 2003; Meyer and Wiesmann, 2006; Kuno et al., 2000; Kamarainen et al., 
2006). 
 
Figure 1.3. Structure of aggrecan: N: amine-terminal, G1, G2, G3: globular 
domains, IGD: interglobular domain between G1 and G2, cp: core 
protein, KS: keratan sulfate region, CS: chondroitin sulfate brush 
region, GAG: glycosaminoglycan chains, C: carboxyl-terminal (Ng et 
al., 2003). 
1.3. Disorders 
As mentioned before, articular cartilage can hold against a dramatic amount of 
mechanical stress, however, it has a very restricted capability of self-repair when it 
encounters a destructing trauma (Hunziker and Rosenberg, 1996; Hunziker, 1999, 
Buckwalter and Mankin, 1998).  
In Europe and North America, the major cause of disabilities is the osteoarticular 
disorders. Moreover, rheumatoid arthritis is very common among the populations, 
effecting about 1% of individuals. It is very abundant, affecting more than two 
third of people over age 55 (Gouze et al., 2007). More dramatically, osteoarthritis 
can be found to strike even more than one third of the adult population in 
industrialized countries (Spagnoli et al., 2007).  
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Figure 1.4. A drawing of aggrecan aggregate: About 100 aggrecan monomers are 
noncovalently bound to a single hyaluronan chain by two link 
proteins. The link proteins are members of a family of hyaluronan-
binding proteins, some of which are cell-surface proteins. This type of 
complex can have a molecular weight of 108 >, occupying a volume of 
2 x 10-12 cm3, which is equal to that of a bacterium (Alberts et al., 
2002). 
Osteoarthritis can be defined as disruption of collagen/proteoglycan network, 
leading to swelling and softening of the tissue. Developmental abnormalities, 
genetic disorders in EMC molecules, excessive usage or limb malposition, and 
metabolic problems, such as diabetes, alcoholism, and being overweighed are the 
causes of osteoarthritis. Furthermore, trauma, caused by direct injury to the joint or 
ligaments, commonly leads to osteoarthritis. Generally being an age-related 
degenerative joint disease, osteoarthritis was shown to be associated with low 
chondrocyte cell density, insufficient synthesis of ECM, and hypertrophy. 
Cartilage tissue engineering is mostly applied to trauma patients since the best data 
of human osteoarthritis were collected from those patients. Hopefully, the results 
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indicate considerably successful prevention or at least retardation of the disease 
(Mollenhauer, 2008; Wang et al., 2006).  
Studies on cartilage degeneration have shown that aggrecan fragments generated 
by aggrecanase action were present in synovial fluids from normal individuals and 
patients with osteoarthritis, rheumatoid arthritis and acute knee injuries 
(Lohmander et al., 1993). As aggrecan molecules are degraded, they are no longer 
able to protect collagen fibers, which will cause proteolytic degradation of 
collagens. Therefore, the reason of articular cartilage degenerations is the 
proteolytic degradation of aggrecan and collagen (Sztrolovics et al., 1997). 
However, their rates of synthesis are increased as well, suggesting an activated 
repair mechanism that is not sufficient in repairing or maintaining the ECM 
homeostasis after all (Koevoet et al., 2008). 
1.4. Tissue Engineering of Articular Cartilage 
Tissue engineering is a promising new therapeutic approach that can overcome the 
problems of autographs allografts and xenografts. In case of cartilage tissue 
engineering, the critical part is the selection of appropriate cell type such that cells 
can be differentiated or progenitor. It essentially depends on fabrication and usage 
of biocompatible and mechanically stable scaffold for cell delivery, furthermore on 
stimulation by applying chondrogenically bioactive molecules that can be 
introduced either in the form of recombinant proteins or through transferring of 
genes. Moreover, application of dynamic, mechanical loading regimen under the 
ultimate aim of conditioning of the engineered tissue constructs that include 
specialized biomechanically active bioreactor design is among the critical 
dependences of cartilage tissue engineering. Therefore, selection of the cell type 
and scaffold, together with the construction of design and stimulation are the 
challenges in cartilage tissue engineering that should be overcome (Kuo et al., 
2006). 
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Figure 1.5. Basic overview of tissue engineering (Csaki et al., 2008). Three main 
factors are essential for tissue engineering: Initially, (A) a compatible 
biomaterial, (B) suitable cells, for instance stem cells,  (C) specific 
bioactive substances, when found all together, they enhance adequate 
cell differentiation and specific tissue formation such as bone, tendon 
and cartilages.  
Among the treatments of traumatic articular cartilage injuries, cartilage 
engineering has an applicable part. The most encouraging goal would be to 
regenerate destroyed cartilage due to osteoarthritis that is the most common type of 
musculoskeletal system diseases among individuals.   
Tissue engineering requires a successful and efficient interaction between 
bioactive factors, cells, their extracellular environment, and a functional matrix or 
scaffold to provide a physical form to the structure (Figure 1.5).  
In some tissue engineering application, the growth and differentiation factors are 
specifically offered together with a matrix material in order to create a promising 
environment for the host cells to populate. For instance, in other applications, in 
vitro treatment of exogenous cells with the growth factor before implantation or 
supplementation of the cells can be observed. 
1.5. Cell Sources  
In cartilage tissue engineering, xenogenic, autologous and allogenic cells are 
considered as the main cell sources. Those cell categories can be divided in 
subcategories according to their characteristics of being a stem cell or a more 
differentiated cell such as primary cells or cell lines. In bone and cartilage tissue 
engineering studies, many types of mature cell lines, such as multipotent 
mesenchymal progenitors are widely used. In other targets than humans, basic 
aspects of in vitro cell behaviors were evaluated using recently developed other 
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types of bone and cartilage cell lines like genetically altered cell lines (sarcoma 
cells, immortalized cells, non-transformed clonal cell lines)  (Yamaguchi et al., 
2002; Meyer and Wiesmann, 2006). 
Mesenchymal stem cells (MSCs) that can be found in the bone marrow in mature 
individuals are responsible for generating chondrocytes. During the 
embryogenesis, when MSC differentiation into chondrocytes takes place, MSCs 
start to secrete a cartilaginous matrix while the cells keep up dividing (Figure 1.6). 
 
  
(a) 
 
  
(b) 
Figure 1.6. (a) Terminal differentiation of a chondrocyte: During natural 
development, a mesenchymal cell turns into a chondroblast and then 
into a chondrocyte, which is an irreversible process (b) Schematic 
illustration of the development of a mesenchymal stem cell into a 
chondrocyte: The development includes the transformation of a 
polymorphic mesenchymal cell (A) to a rounded chodroblast (B), 
which characterizes its own cavity, in interaction with the ECM (C). 
The number of chondrocytes that will share this lacuna and how the 
chondral capsule should be developed must be determined. 
According to these conditions, the mechanically loadable 
intercellular substance is then developed (D– E) (Minuth et al., 
2005). 
Primary chondrocytes, another cell source for cartilage regeneration, can be 
isolated from articular cartilage explants. When isolated, these chondrocytes 
dedifferentiate; in other words, stop expressing collagen type II and aggrecan, lose 
their characteristic phenotypes, which are round-shaped, adopt a fibroblastic shape, 
and start to proliferate. These chondrocytes can be induced to redifferentiate by 
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culturing them in a suitable environment that includes differentiation factors like 
TGF-β1. Cultured chondrocytes are less multipotent than MSCs; hence, it is less 
expected to generate unrelated cell types when these chondrocytes are used for the 
repair of cartilage tissue (Kaplan et al., 2006, Pittenger and Marshak, 2001). 
Fibroblasts can easily be obtained in high numbers and be directed toward 
chondrogenic differentiation. French et al. (2004) have demonstrated that human 
dermal fibroblasts induced with IGF-1 and cultured on aggrecan formed dense 
aggregates that stain positive for GAGs and collagen type II. In addition, induced 
pluripotent stem (IPS) cells developed from adult human fibroblasts, and adipose-
derived stem cells can be counted as cell sources for cartilage tissue engineering in 
the case of chondrocyte shortage (Wang et al., 2008).  
1.6. Biomaterials  
A biomaterial should be biodegradable or bioresorbable to permit the 
reconstruction of a normal tissue, and its degradation products should not provoke 
inflammation or toxicity if it is going to be used in tissue engineering. (Kim et al., 
2000). It should be able to regulate cell behavior, which includes cell adhesion, 
growth, and differentiation, in order to promote development of a functional new 
tissue. In addition, the final configuration of the biomaterial should have a large 
surface area-to-volume ratio for better cell-polymer interactions, ECM 
regeneration, and for minimal nutrient and waste diffusion constraints. Finally, it 
should be reproducibly processable with appropriate mechanical properties, and its 
degradation rate should be adjustable to match the rate of tissue regeneration by 
the cells. 
1.6.1. Natural Biomaterials 
Naturally derived macromolecules have potential advantages of biocompatibility, 
cell controlled degradability, and intrinsic cellular interaction (biological 
recognition). However, they may exhibit batch-to-batch variations and generally 
exhibit a narrow and limited range of mechanical properties (Lee et al., 2001). 
They can be obtained from various sources: ECM (collagen, hyaluronic acid) or 
plasma (fibrin) of mammalian tissues, crustaceans and seaweeds (chitin and 
alginate, respectively), microorganisms (polyhydroxyalkanoates). 
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1.6.2. Synthetic Biomaterials 
In contrast to natural macromolecules, synthetic polymers can be prepared to have 
more precisely controlled structures and properties (Lee et al., 2001). They can be 
produced reproducibly on a large scale with relatively controlled strength, 
degradation rate, and microstructure, like porosity, by either altering the 
ingredients employed or polymer-processing methods (Marler et al., 1998). 
Properties of synthetic polymers can be altered by varying functional groups 
(backbone or side chain), polymer architecture (linear, branched, comb or star) and 
polymer combinations (polymer blends, interpenetrating networks or chemically 
bonded copolymers) (Wong et al., 1997). Poly (-hydroxy acids) such as poly 
lactic acid (PLA) and its copolymers with glycolic acid (PLGA) are the most 
commonly used polymers in medicine besides other synthetic polymers like  
poly(anhydrides) and poly(ortho-esters). 
PLA, PGA, and PLGA have gained FDA approval for human use for a variety of 
applications, including sutures. Since these polymers are thermoplastics, they can 
be easily formed into desired shapes by various techniques including molding, 
extrusion or by solvent casting. PGA, which has the simplest structure among 
linear aliphatic polyesters, is highly crystalline and thus has a high melting point 
and low solubility in organic solvents. PLA is more hydrophobic than PGA due to 
the presence of an extra methyl group in the structure of lactic acid and dissolves 
more readily in organic solvents (Pachence and Kohn, 1997).  
The degradation rate of the copolymers can be tailored from several weeks to 
several years by alteration of their crystallinity, molecular weight, and the ratio of 
lactic to glycolic acid. However, it should be noted that there is no linear 
relationship between the ratio of glycolic acid to lactic acid and the 
physicochemical properties of their copolymers. Although PGA is crystalline, this 
feature is lost in PGA-PLA copolymers and degradation takes place more rapidly 
than either PGA or PLA. The ester bonds in these polymers are hydrolytically 
labile and these polymers degrade by nonenzymatic hydrolysis. PGA hydrolyses in 
water to glycolic acid, which can be converted enzymatically to glycine to be used 
in protein synthesis or pyruvate that will enter the tricarboxylic acid cycle and 
eventully eliminated from the body in the form of carbon dioxide and water. PLA 
12 
 
also undergoes hydrolytic deesterification into lactic acid, which becomes 
incorporated into the tricarboxylic acid cycle to be converted to CO2 and H2O. 
Linear aliphatic polyesters such as PLA, PGA, and copolymers (PLGA) are 
synthetic biocompatible polymers that are approved by Food and Drug 
Administration (FDA) and therefore they are widely used (Figure 1.7). Their rate 
of biodegradation and mechanical characteristics may be altered simply by 
changing their copolymer ratio. Moreover, they are proved to be applicable in 
many tissue engineering applications, and also are used in drug delivery studies 
based on the fact that their degradation products, formed as a result of their 
hydrolysis, can be naturally found as parts of metabolic pathways in human body 
(Lo et al., 1996; Richardson et al. ,2001; Jang and Shea, 2003; Nof and Shea., 2002 
Sengupta et al., 2005; Freed et al., 1993; Sarazin et al., 2004). 
 
Figure 1.7. The structure of poly (lactic-co-glycolic acid) (PLGA). 
N-isopropylacrylamide (NIPAM) has been one of the most commonly studied 
thermoreversible synthetic biomaterial. The polymers exhibit a solubility change as a 
function of temperature, which could be utilized for convenient delivery of proteins 
and cells (Jiang et al., 2006). 
It forms a three-dimensional hydrogel when crosslinked with N,N’-methylene-bis-
acrylamide (MBAm) or N,N’-cystamine-bis-acrylamide (CBAm). When heated in 
above 33°C, it undergoes a reversible phase transition from a swollen hydrated state 
to a shrunken dehydrated state, losing about 90% of its mass. Since PNIPAm expels 
its liquid contents at a temperature near that of the human body, PNIPAm has been 
investigated by many researchers for possible applications in controlled drug 
delivery (Chung et al., 1999). 
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Figure 1.8 Formula of a single NIPAM molecule (Chung et al., 1999). 
1.7. Biological stimulation 
Growth factors, found in polypeptidic structures, have roles in the cellular 
communication system (Nimni, 1997). Their action is based on signal transmission 
under the ultimate aim of modulating cellular activity by either inhibiting or 
enhancing proliferation, differentiation, migration, or gene expression (McKay and 
Leigh, 1993). In general, growth factors exhibit pleiotropic behaviors, such that 
same growth factor may have different cells as targets in order to create similar or 
distinct effects. Furthermore, another effect called redundancy is a part of growth 
hormone properties, meaning that they can exert the same effect for a specific cell 
type. Their exhibition of stimulation or inhibition can be either through an 
endocrine (released directly into the blood stream), paracrine (diffusion to 
neighbor target cell) or autocrine (source and target cell are the same) fashion. 
Their action starts when they bind to specific receptors that are found on the target 
cell membrane (Le Roith and Blakesley, 2000). When a threshold amount of 
receptors becomes activated, the signal transduction process that ends up in a 
specific cellular activity is created (Vasita and Katti, 2006). Therefore, it can be 
concluded that effects of growth factors are both receptor concentration and time 
dependent (Croucher et al., 1999). Some of those growth factors are studied and 
characterized in detail and consequently, they are readily used as a part of 
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recombinant technology techniques and moreover, this enables a more articulated 
research of their potential in various tissue engineering applications.  
 Insulin-like growth factor 1 (IGF-1), a 70 amino acids polypeptide, is related to 
insulin structure and growth hormone regulates its synthesis. Besides, it is 
responsible for driving DNA synthesis in different cell types including 
chondrocytes, and also stands for most of the chondrocyte stimulating activity 
found in serum (Croucher et al. 1999; Clemmons, 2000). In case there is a 
mechanical stimulation found, insulin-like growth factor-I (IGF-I) can dramatically 
increase biosynthesis levels (Bonassar et al.2001; Jin et al. 2003). Additionally, 
increasing proteoglycan and collagen type II synthesis are among the positive 
effects of IGF-1, next to chondrocytes proliferation (Makower et al. 1989; Darling 
et al., 2005; Morales, 1997; Loeser et al., 2003; De Mattei et al. 2004). 
Furthermore, chondrocyte-based repair of osteochondral defects is suggested to be 
enhanced by IGF-1, in vivo (Fortier et al. 2002). 
Transforming growth factor-β1 (TGF-β1) functions in enhancing matrix 
fabrication in engineered constructs, as well as stimulating cellular proliferation 
(Guerne et al. 1994; Darling and Athanasiou 2003; Blunk et al. 2002; van der 
Kraan et al.1992). This homodimeric, 25 kD protein is a member of a superfamily 
consisting of 100 related proteins. The bone morphogenetic proteins (BMPs) and 
growth and differentiation factors (GDF) are the proteins found in this superfamily 
(Chin et al., 2004). 
Synthesis of extracellular matrices is under the control of TGF- β1 and this control 
is exerted through the stimulation of the collagen, fibronectin (Ignotz et al., 1987) 
and proteoglycan (Chen et al., 1987; Morales, 1991) synthesis. Furthermore, TGF - 
β1 positively directs cartilage differentiation and repair (Boumediene et al., 1995; 
Johnstone et al., 1998; Grimaud et al., 2002; Olney et al., 2004; Darling et al., 
2005). On the other hand, this factor is known for its specific negative side effects. 
Those undesired traits manifest, such as inflammatory responses and osteophyte 
formation in articular cartilage defects, if it is located in the knee joint too long 
(van Beuningen et al., 2000). 
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1.8. Controlled Delivery Systems 
The term “controlled delivery” can be described as the administration of bioactive 
agents to control the in vivo location and concentration of these molecules for 
treatment of diseases (Uchegbu, 2006). Traditional methods of drug administration 
generally include pills, eye drops, ointments, and injections in veins as solutions, 
while novel drug delivery approaches have been started to be used nowadays. 
Those methods are carried out as drug modifications, usage of small particles for 
drug entrapment purposes and their insertion into the bloodstream, as well as 
enclosement of drugs within pumps or other polymeric materials and their 
replacement in the target body compartment.  
In recent years, the interest in drug delivery has increased because of the increasing 
need of safe drugs that are able to target their destinations with minimum side 
effects. A perfect drug should reach only its target site, using the lowest 
concentration without negatively affecting the surrounding tissues that are out of 
target range. Current delivery systems use soluble, simple macromolecules 
(monoclonal antibodies, synthetic polymers, polysaccharides, biodegradable 
polymers), as well as complex multicomponent molecules (cells, cell ghosts, 
erythrocytes, lipoproteins, liposomes, microcapsules, microparticles) (Pierigé et 
al., 2008). 
An ideal drug delivery system should be made self-powered and computer-
controlled nanorobots, and be capable of precise timing and delivering of 
pharmaceuticals to the specific target in the body. Although such systems are not 
established yet, cell based delivery systems are the closest ones to the ideal drug 
delivery system: transduced cells and cell carriers. In the former case, cells are 
transduced by gene transfer method with selected genes that express fluorescent 
proteins in order to observe the cell’s behaviour in vivo, or to correct a genetic 
defect, or to make the target cell exposed to the action of a selected drug (i.e. by 
expressing Tymidine kinase). In the latter method, cells can be loaded with drugs 
that will be released in circulatory system, or to the target cells. Macrophages and 
erythrocytes have been reported as the most useful cell carriers for drug delivery 
(Pierigé et al., 2008). 
Polymeric drug delivery systems are also widely used as drug delivery systems. 
Studies on these systems reported polymers that are capable of extending the 
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function of drug by entrapping the drug within matrices, converting drug release in 
the direction of tumors, direct therapeutic genes or oligonucleotides into cells, and 
triggering the release of drug only when there is a defined change in temperature or 
pH or when activated by an enzyme. Changing the water solubility of polymers, 
increasing their chain lengths via cross-linking them with copolymers and other 
groups, materials with enhanced drug delivery properties are produced, such as 
prolonged drug availability when formulated as hydrogels or microparticles 
(Uchegbu, 2006).  
Biodegradable drug and growth factor carriers, such as polymer hydrogels and 
microparticles, collagen, fibrin, chitosan, and hyaluronan based materials, have been 
studied for cartilage tissue engineering. For instance, collagen sponges filled with 
BMP-2 (bone morphogenetic protein-2), and PLGA nanospheres loaded with 
betamethasone (a water-soluble corticosteroid) have been successfully applied for 
repairing of cartilage defects (Holland and Mikos, 2003). 
1.9 Aim 
The objective of this thesis is the investigation of pH and temperature sensitive 
nanospheres as a tool for growth factor delivery systems on  PLGA porous scaffolds 
for cartilage tissue engineering.   
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Isolation and Growth of Mesenchymal Stem Cells and Articular Cartilage 
Cells 
2.1.1.1. Isolation of Mesenchymal Stem Cells From Bone Marrow 
 Dulbecco’s Modified Eagle Medium (DMEM; low glucose) (Gibco – 
Invitrogen, USA) 
 Dulbecco’s Modified Eagle Medium (DMEM; high glucose) (Sigma-Aldrich 
Corporation, Germany) 
 Fetal Bovine Serum (FBS) (Gibco – Invitrogen, USA) 
 Penicilin/Streptomycin Solution (Biochrom Ac, Germany) 
 T75 Tissue Culture Flasks (Orange Scientific, Belgium) 
 Petri dishes (ISOTHERM, Turkey) 
 Sterile syringes (Set®Inject, Turkey) 
2.1.1.2. Mesenchymal Stem Cell Culturing 
 Phosphate Buffered Saline (D-PBS, 500 mM, pH 7.4) (Gibco – Invitrogen, 
USA) 
 Dulbecco’s Modified Eagle Medium (DMEM; high glucose) (Sigma-Aldrich 
Corporation, Germany) 
 Fetal Bovine Serum (FBS) (Gibco – Invitrogen, USA) 
 Penicilin/Streptomycin Solution (Biochrom Ac, Germany) 
2.1.1.3. Trypsinization and Subculturing of Mesenchymal Stem Cells 
 Trypsin/EDTA (Gibco – Invitrogen, USA) 
 Fetal Bovine Serum (FBS) (Gibco – Invitrogen, USA) 
 Dulbecco’s Modified Eagle Medium (DMEM; high glucose) (Sigma-Aldrich 
Corporation, Germany) 
 Propidium Iodide (PI) (INCYTO, Korea) 
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 C-Reader Automatic Cell Counter Reagents (INCYTO, Korea)  
 C-Reader Chip (INCYTO, Korea) 
 T75 Tissue Culture Flasks (Orange Scientific, Belgium) 
2.1.2. Preparation and in vitro Characterization of Nanospheres 
2.1.2.1. Preparation of Growth Factor Loaded PLGA Nanospheres 
 Dichloromethane (DCM) (AppliChem, Germany) 
 Poly(lactic acid-co-glycolic acid) (PLGA, 50:50) (Boehringer-Ingelheim, 
Germany) 
 Ultrasonic Homogenizer (4710 series, Cole-Parmer Instruments, USA) 
 Polyvinyl Alcohol (PVA) (Fluka, Switzerland) 
 Tris (AppliChem, Germany) 
 Hydrochloric Acid (HCl) (Riedel-de Haen, Germany) 
2.1.2.2. Preparation of Growth Factor Loaded NIPAM Nanospheres 
 MBA crosslinked  poly(NIPAM)  
 Acetone (AppliChem, Germany) 
2.1.2.3. In vitro Characterization of Growth Factor Loaded Nanospheres 
 Dulbecco’s Modified Eagle Medium (DMEM; high glucose) (Sigma-Aldrich 
Corporation, Germany) 
 Penicilin/Streptomycin Solution (Biochrom Ac, Germany) 
 Insulin – Transferrin – Selenium (ITS, GIBCO – Invitrogen, USA) 
 Linoleic acid (Sigma-Aldrich Corporation, Germany) 
 L-Proline (Sigma-Aldrich Corporation, Germany) 
 Sodium-pyruvate (Sigma-Aldrich Corporation, Germany) 
 Albumin, Bovine Fraction V (Sigma-Aldrich Corporation, Germany) 
 L-ascorbic acid (AppliChem, Germany)  
 Dexamethasone (AppliChem, Germany) 
 Empty PLGA nanospheres (EP) 
 Empty NIPAM nanospheres (EN) 
 IGF-I loaded PLGA nanospheres (IP) 
 TGF-β1 loaded NIPAM nanospheres (TN) 
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2.1.3. Preparation and in vitro Characterization of Nanospheres on PLGA 
Scaffolds    
2.1.3.1. Porous PLGA  Scaffold Preparation 
 Poly(lactic acid-co-glycolic acid) (PLGA, 50:50) (Boehringer-Ingelheim, 
Germany) 
 Dichloromethane (DCM, AppliChem, Germany) 
 NaCl crystals (300 μm–500 μm) (Sigma-Aldrich Corporation, Germany) 
 Glass Petri Dishes (ISOTHERM, Turkey) 
 Distilled water 
 Freeze-dryer (Thermo, Savant Modulyo Freeze Drying Systems, USA) 
2.1.3.2. Scanning Electron Microscopy of Empty Porous PLGA Scaffolds 
 Sputter Coater (Bal-tec SCD 005, Germany) 
 Scanning Electron Microscope (Carl Zeiss EVO, Germany) 
2.1.3.3. Preparation of Cell Containing Porous PLGA Scaffolds 
 Ethanol, absolute (J.T.Baker, Holland) 
 Dulbecco’s Modified Eagle Medium (DMEM; low glucose) (Gibco – 
Invitrogen, USA) 
 Chondroitin Sulfate A (Sigma-Aldrich Corporation, Germany) 
 Vacuum system (BioVac225 Suction Systems) 
 Nanospheres (EP, EN, IP, TN) 
 C-reader Automatic Cell Counter (INCYTO, CRM-350) 
 Alginic acid (Sigma-Aldrich Corporation, Germany) 
 Phosphate Buffered Saline (D-PBS, 500 mM, pH 7.4) (Gibco – Invitrogen, 
USA) 
 24-well plates (Orange Scientific, Belgium) 
2.1.3.4. Cell Growth on Cell Containing Porous PLGA Scaffolds 
 CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega, 
USA) 
 MTS Cell Proliferation Assay Solution (Promega, USA) 
 Dulbecco’s Modified Eagle Medium (DMEM; low glucose) (Gibco – 
Invitrogen, USA) 
 96-well plates (Orange Scientific, Belgium) 
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 Elisa Plate Reader (Bio-Tek, Elx800, USA) 
2.1.3.5. Scanning Electron Microscopy of Cell Containing Porous PLGA 
Scaffolds 
 Cacodylic Acid Sodium Salt Trihydrate (AppliChem, Germany) 
 Glutaraldehyde Solution, Grade I, 25% (Sigma-Aldrich Corporation, 
Germany) 
 Sputter Coater (Bal-tec SCD 005, Germany) 
 Scanning Electron Microscope (Carl Zeiss EVO, Germany) 
2.1.3.6. Confocal Microscopy with Collagen Type II and Aggrecan Double 
Staining of Cell Containing Porous PLGA Scaffolds 
 Formaldehyde (Fluka, Switzerland) 
 Tween® 20 (AppliChem, Germany) 
 Methanol (J.T.Baker, Holland) 
 Phosphate Buffered Saline (D-PBS, 500 mM, pH 7.4) (Gibco – Invitrogen, 
USA) 
 Fetal Bovine Serum (FBS) (Gibco – Invitrogen, USA) 
 Collagen Type II, mouse monoclonal IgG2b (Santa Cruz Biotechnology, Inc., 
USA) 
 Aggrecan, rabbit polyclonal IgG (Santa Cruz Biotechnology, Inc., USA) 
 Goat anti-mouse IgG – FITC (Santa Cruz Biotechnology, Inc., USA) 
 Alexa Fluor ® 647, goat anti-rabbit IgG (Invitrogen., USA)  
 Mowiol (Calbiochem, Germany) 
 
2.2. Methods 
There are two sets of experiments in this study: 1- the effect of nanospheres on cells 
seeded into 24-well plate tissue culture polystyrene (TCPS), 2- the effect of the same 
nanospheres on cells seeded into 3D scaffolds. In the first set, different mediums 
containing different nanospheres were added onto the cells. In the second set, the 
same procedure was applied to the cells seeded on scaffolds (Figure 2.1) 
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Figure 2.1. Scheme of the experimental pathway. 
2.2.1. Isolation and Growth of Mesenchymal Stem Cells  and Articular 
Cartilage Cells 
2.2.1.1. Isolation of Mesenchymal Stem Cells From Bone Marrow 
6 week old, 150-170g male Sprague-Dawley rats’ bone marrow stromal osteoblastic 
cells were obtained for isolation. After clearing the femur, Dulbecco’s Modified 
Eagle Medium including 1000 unit/mL streptomycin was used to wash the bones. 
The two extremes of the femur were cut and the marrow was placed into petri dishes 
containing 5 mL growth medium  (DMEM with %20 fetal bovine serum (FBS) and 
100 unit/mL penicillin and 100 unit/mL streptomycin) by using syringe. The cell 
groups were separated by continuous pipetting method and they were centrifuged at 
2000 rpm for 5 min. The pellet was dissolved in 12 mL primer culture medium and 
cultivated in T-75 flask. The cells were incubated in CO2 incubator at 37°C, in 5% 
CO2 and 90% humidity ambient.    
2.2.1.2. Mesenchymal Stem Cell Culturing 
The hematopoietic stem cells and other unhold cells were excluded from the flasks 
by washing with PBS (500 mM, pH 7.4). DMEM-high glucose with 10%FBS and 
100 unit/mL penicillin-streptomycin was added on cells. The cells were incubated at 
37°C, in 5% CO2 and 90% humidity ambient and the medium was refreshed every 
other day. 
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2.2.1.3. Trypsinization and Subculturing of Mesenchymal Stem Cells 
At the end of 7 to 10 days of incubation,  cells were detached with Trypsin (0.25%)-
EDTA treatment for 5 min at 37°C. After detachment, trypsin was deactivated with 
serum and the cells were collected by centrifugation at 2300 rpm for 5 min. Pellet 
was resuspended in growth medium. Then, total cell number was counted with C-
reader automatic cell counter. Propidium iodide (PI) provided the DNA staining and 
C-Reader Chip two channel hemocytometer chips were used for the counting. The 
cells were transferred into two 75 cm² flasks. The subcultures were incubated at 
37°C, in 5% CO2 and 90% humidity ambient and the medium was refreshed every 
other day.  
2.2.1.4. Determination of  Mesenchymal Stem Cell Number 
To determine the viable mesenchymal cell number, C-reader automatic cell counter 
was used. Propidium iodide (PI) provided the DNA staining and C-Reader Chip two 
channel hemocytometer chips were used for the counting. One hundred μl cell 
containing medium mixed with total cell counting solution and non-viable cell 
counting solution.  
 2.2.1.5. Isolation and Growth of Cartilage Cells From Articular Cartilage 
The Sprague-Dawley rats’ knee joint cartilage was isolated under sterile conditions. 
RPMI 1640 with 1000 unit/mL penicillin-streptomycin was used to wash the 
samples. The cartilage tissue samples that were taken into 35 mm petri plates were 
cut into small pieces around 0.5 mm by using scalpel. After washing and cleaning the 
samples with RPMI 1640 medium, they were incubated overnight in 2 mg/mL type-
II collagenase solution for enzymatic cell separation. At the end of 48 hours of 
incubation, the cells were pipetted and transferred into a new tube.  
RPMI 1640 (3 mL) medium was added onto the cells and they were centrifuged for 5 
min. Then,  10 mL culture solution was added onto the cells in the pellet and they 
were homogenized by glass pipette. The sample was resuspended and separated in 
flasks. Three mL RPMI 1640 medium (100 mL, 10% mL FBS, 1.5 mL L-glutamine, 
1 mL penicillin-streptomycin) was added onto each flask and the primer cells were 
incubated at 37°C’, in %5 CO2 and %90 humidity ambient. The adhesion of the cells 
on the flask surface and the growth of cells were visualized by inverted microscope 
(Nikon, Eclipse, TS100, Japan). The medium was refreshed every other day. 
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2.2.1.6. Articular Cartilage Cell Culturing 
The hematopoietic stem cells and other unhold cells were excluded from the flasks 
by washing with PBS (500 mM, pH 7.4). DMEM-high glucose with 10%FBS and 
100 unit/mL penicillin-streptomycin was added on cells. The cells were incubated at 
37°C, in 5% CO2 and 90% humidity ambient and the medium was refreshed every 
two days. 
2.2.1.7. Trypsinization and Subculturing of Articular Cartilage Cells 
At the end of 7 to 10 days of incubation, cells were detached with Trypsin (0.25%)-
EDTA treatment for 5 min at 37°C. After detachment, trypsin was deactivated with 
serum and the cells were collected by centrifugation at 2300 rpm for 5 min. Pellet 
was resuspended in growth medium. Then, total cell number was counted and the 
cells were transfered into two 75 cm² flasks. The subcultures were incubated at 37°C, 
in 5% CO2 and 90% humidity ambient and the medium was refreshed every other 
day. 
2.2.1.8. Determination of Articular Cartilage Cell Number 
To determine the viable Articular Cartilage cell number, C-reader automatic cell 
counter was used. Propidium iodide (PI) provided the DNA staining and C-Reader 
Chip two channel hemocytometer chips were used for the counting. One hundred μl 
cell containing medium mixed with total cell counting solution and non-viable cell 
counting solution.  
2.2.2. Preparation and in vitro Characterization of Nanospheres 
2.2.2.1.  Preparation of Growth Factor Loaded PLGA Nanospheres  
Nanospheres encapsulating IGF-I were prepared by the double emulsion-solvent 
evaporation technique by Pınar Yılgör (METU, BIOMAT Research Center, 
Biotechnology Dept). Briefly, the agent was disolved in dichloromethane (DCM) 
containing PLGA by probe sonication for 15 s (Ultrasonic homogenizer, 4710 series, 
Cole-Parmer Instruments, USA) at an output of 50 W. The first emulsion (w1/o) was 
added into an aqueous solution of PVA (4% (w/v)) to form the second emulsion by 
sonication (w1/o/w2). The double emulsion was then added into PVA (0.3% (w/v)) 
and the organic solvent was evaporated by vigorous stirring overnight. Nanospheres 
were collected by centrifugation (15000 g, 10 min) and washed twice with Tris-HCl 
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(pH 7.4). The nanospheres were then resuspended in the buffer and lyophilized (-
80oC, 6.10-2 mbar).  
2.2.2.2. Preparation of Growth Factor Loaded NIPAM Nanospheres  
Nanoparticles were prepared by nanoprecipitation method by Banu Bayyurt  (METU, 
BIOMAT Research Center, Biotechnology Dept). MBA crosslinked poly(NIPAM)  
(0.04%, v/v) were precipitated from organic solvent, acetone, into cyclohexane 
without using any surfactant. Model protein (BSA) or growth factor (TGF-β1) 
loading was accomplished by equilibrium partitioning method. In a typical loading 
study, the solution of agent (2 mg) was added to the nanoparticle dispersion (50 
mg/mL in PB solution) to form the nanoparticle suspension. The suspension was 
cooled to 4 °C, stored for 24 h, and heated quickly to 37 °C. Nanoparticle suspension 
containing free agent was centrifuged at 13 500 rpm, 20 min and after removing 
supernatant, nanoparticles were dried at 37 oC in the oven, overnight. 
2.2.2.3. In vitro Characterization of Growth Factor Loaded Nanospheres 
For in vitro characterization of nanospheres, different medium contents were 
prepared (Table 2.1). For that purpose, cartilage differentiation medium (DMEM-
high glucose with 100 unit/mL penicillin-streptomycin, 6.25 μg/mL insulin, 6.25 
μg/mL transferrin, 6.25 μg/mL selenic acid, 5.33 μg/mL linoleic acid,  40 μg/mL 
proline, 100 μg Na-pyruvate, 1.25 mg/mL BSA, 50 μg/mL L-ascorbic acid ve 100 
nM dexamethasone) was put into 24 well plates containing cells. Then, empty PLGA 
nanospheres (EP), empty NIPAM nanospheres (EN), IGF loaded PLGA nanospheres 
(IP), TGF-β1 loaded NIPAM nanospheres (TN), IGF loaded PLGA nanospheres and 
IGF loaded NIPAM nanospheres both (IPTN) were added onto each well, 
respectively. Each combination was prepared three times. 
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Table 2.1.  Medium contents of cell seeded samples in 24 well plate. 
 
Sample 
PLGA 
nanosphere 
NIPAM 
nanosphere 
 
Cell 
Sample 1 (OC)   X 
Sample 2 (EP) X (empty)  X 
Sample 3 (EN)  X (empty) X 
Sample 4 (IP) X (IGF-1)  X 
Sample 5 (TN)  X(TGF-1) X 
Sample 6 (IPTN) X (IGF-1) X (TGF-1) X 
2.2.2.4. Determination of Cell Growth - Calibration Curve  
A calibration curve of cell numbers vs absorbance was constructed. Certain numbers 
of cells were seeded onto 24 well plate wells and waited for two hours. CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (MTS) was used to determine the 
cell density. DMEM low glucose medium was mixed with MTS one solution with a 
ratio 5:1. Cells were washed with PBS to remove artifacts. 500 μL of MTS- medium 
mix was added onto each sample in the 24-well plate and incubated for 4 h at 37ºC in 
a CO2 incubator. After 4 h of incubation, 200 μL of solution from each well was 
transferred into a new 96-well plate  in triplicate. Absorbance was determined at 490 
nm using an Elisa Plate Reader (Bio-Tek, Elx800, USA). 
26 
 
 
Calibration Curve
y = 0.0187x
0
0.5
1
1.5
2
2.5
3
0 20 40 60 80 100 120 140 160
Cell Number
Ab
so
rb
an
ce
 
 
Figure 2.2 Calibration curve of bone marrow mesenchymal stem cells of rat with 
MTS for 4 hours. 
2.2.2.5. Determination of Cell Growth in Nanosphere Containing Medium 
In order to determine the cell growth in nanosphere containing medium, 24 well 
plates with cells and different medium compositions were prepared as it was 
described in section 2.2.2.3. Each cell and medium composition was prepared in 
triplicate for days Days 1, 7 and 14. At the end of the time periods, MTS assay was 
carried out onto each sample as it was described in section 2.2.2.4. A graph of Cell 
Numbers vs Absorbance was constructed. Cell numbers were calculated according to 
the calibration curve constucted before.  
2.2.2.6. RT-PCR  
Total RNAs were isolated from  the cells in different medium composition 
(described in section 2.2.2.3) by using RNeasy Mini Kit. First-strand cDNA 
synthesis was performed by using Sensiscript Reverse Transcriptase. Primer sets for 
each gene are listed in Table 2.2. For optimization of the primers, the amplified DNA 
fragments at different tempratures were visualized through 1.5% agarose gel 
electrophoresis, stained with ethidium bromide and photographed under UV light. In 
real-time PCR experiments for each sample 12,5 μl SYBR Premix Ex Taq (2X), 0,5 
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μl PCR forward primer, 0,5 μl PCR reverse primer, 2 μl template, 9 μl dH2O were 
used in Bio-Rad iCycler™ real time system.  
Table 2.2. Primers for PCR 
Marker Sequence Length
Beta actin  forward 5’ TTCTACAATGAGCTGCGTGTG 3’  
reverse  5’ GCTGGGGTGTTGAAGGTC 3’ 
125 bp 
Collagen type II forward 5’ TGAACAACCAGATCGAGAGCA 3’  
reverse  5’ CCAGTCTCCATGTTGCAGAAG  3’  
175 bp 
2.2.2.7. Determination of ECM Storage in Cell Culture by Biochemical 
Methods- DMMB (1,9-dimethylmethylene blue) Assay  
Determination of ECM storage in cell culture was carrried out with the cells in 
different medium composition (described in section 2.2.2.3) by using DMMB assay.  
Cells seeded on polypropylene tubes. At the end of each time period, samples were 
digested in 300 µg/mL of papain in 20 mM sodium phosphate (pH 6.8), 1 mM 
EDTA and 2 mM dithiothreitol at 60°C for 1 hour. Sixteen mg/L DMMB solution 
was preparared with glycine, NaCl and HCl and final pH was adjusted to 3. Digested 
samples (100 μL) were mixed with 200 μL of DMMB solution and the absorbance 
was measured at 525nm using Thermo LabSystems Multiscan Spectrum (Model 
no1500, USA) microplate reader. 
2.2.2.8. Determination of ECM Storage in Cell Culture by Biochemical 
Methods-Hydroxyproline Assay 
Fifty µL of the different set of the same samples described in section 2.2.2.7  were 
hydrolyzed with 50 µL of 12M HCl for 18 h at 100 °C. The hydrolysate was then, 
dried in a vacuum desicator over the NaOH pellets. The residue was dissolved in 150 
µL water, transferred into a 96-well plate, and dried in a hood. Sixty µL of water was 
then added onto each well followed by addition of 20 µL of assay buffer (1-
propanol/water/pH 6 buffer*; 3:2:10 ratio). The solution was allowed to shake until 
the residue was fully solubilized. Then, chloramine T reagent (40µL, 0.050 mol/L), 
was added onto each sample and they were allowed to shake for 15 min at room 
temperature. DMBA reagent (80 µL  dimethylaminobenzaldehyde (2 g), 1.25 mL of 
1-propanol, 2.75 mL of perchloric acid) was added and the plate was incubated on a 
shaker for 20 min at 70 °C. After the plate was allowed to cool, absorbances were 
determined at 570 nm by using Thermo LabSystems Multiscan Spectrum (Model 
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no1500, USA) microplate reader. Data were converted to nanograms of 
hydroxyproline based on a standard curve that consists of hydroxyproline levels 
ranging from 20–2000 ng/well (Pratta et al., 2003). 
pH 6 buffer: (0.24 M citric acid, 0.88 M anhydrous sodium acetate trihydrate, 0.88 
M anhydrous sodium acetate, 0.21 M acetic acid, 0.85 M sodium hydroxide). 
2.2.2.9. Determination of Cell Morphology in Cell Culture by 
Immunohistochemical Methods-Alexa Fluor® 546 Phalloidin and TO-PRO®-3 
Confocal Microscopy Staining  
Cell morphology in cell culture was also carrried out with the cells in different 
medium composition (described in section 2.2.2.3) by using Alexa Fluor® 546 
Phalloidin and TO-PRO®-3 Confocal Microscopy Staining.  
First, the samples were washed with PBS and incubated in 3% FBS/PBS for 10 min. 
Phalloidin was prepared in FBS/PBS (1.5%, 1:100). The serum was extracted from 
the samples by pipetting and antibody (Ab) solution was added onto each samples. 
The samples were incubated at the room temperature for 20 min to 1 h. After the 
incubation, the samples were washed with PBS for three times and every time they 
were waited for 5 min.. TO-PRO®-3 was prepared in 2% FBS/PBS (1:100). After 
the addition of TO-PRO®-3, the samples were incubated at the room temperature for 
15 min. After the incubation, the samples were washed with PBS for three times and 
every time they were waited for 5 min.. They were mounted by 80- 100 µL mounting 
medium. The images were obtained with a Leica TCS SP2 Laser Scanning Spectral 
Confocal System (Leica microsystems GmbH, Heidelberg, Germany).  
2.2.2.10. Determination of ECM Deposition in Cell Culture by 
Immunohistochemical Methods-Collagen Type II and Aggrecan Confocal 
Microscopy Double Staining 
Another way to determine cartilage marker proteins in cell culture with different 
medium composition (described in section 2.2.2.3) is the double staining of samples 
with collagen type II and aggrecan and observe them under the Confocal 
Microscopy.  
In this method, the samples were washed with PBS for three times and waited in 3% 
FBS/PBS for 10 min. Collagen Type II primer Ab was prepared in 1.5% FBS/PBS 
(1:100). The serum was extracted from the samples by pipetting and Ab solution was 
added onto each samples before washing step. The primers were incubated at room 
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temperature for 1-18 h. After the incubation, the samples were washed with PBS for 
three times and every time the samples were waited for 5 min. Collagen type II 
secondary Ab (FITC) were prepared in 1% FBS/PBS (1:200). After the washing 
steps, secondary Ab solution was added onto each samples and they were incubated 
at 370C for 45 min. After the incubation, the samples were washed with PBS for 
three times and every time they were waited for 5 min. Another primary antibody, 
aggrecan, was prepared in 1.5% FBS/PBS (1:200). After the washing steps, 
Aggrecan antibody solution was added onto each samples and they were incubated at 
the room temperature for 1-18 h. After the incubation, the samples were washed with 
PBS for three times and every time the samples were waited for 5 min. Secondary 
aggrecan antibody was prepared in 1% FBS/PBS (1:200). After the washing steps, 
Secondary aggrecan Ab solution was added onto each samples and they were 
incubated at 370C for 45 min. After the incubation, the samples were washed with 
PBS for three times and they were mounted by 80-100 µL mounting medium. The 
images were obtained with a Leica TCS SP2 Laser Scanning Spectral Confocal 
System (Leica microsystems GmbH, Heidelberg, Germany). 
2.2.3. Preparation and in vitro Characterization of Nanospheres on PLGA 
Scaffolds    
2.2.3.1. Porous PLGA Scaffold Preparation 
PLGA  Scaffolds (8%, 50:50) were prepared in DCM. In order to obtain porous 
structure, NaCl crystals (300 μm–500 μm) were used. The polymer solution was 
poured into the glass. Petri plates that were covered with aluminum foil. Plates were 
left in fume hood for DCM evaporation. For the following two days, scaffolds were 
placed in distilled water on a magnetic stirrer in order to remove salt particles from 
the sponges. The scaffolds were removed from the water, freezed at -20 oC and 
lyophilized using a freeze-dryer (Thermo, Savant Modulyo Freeze Drying Systems, 
USA). After lyophilization, the scaffolds were cut to be 13 mm in diameter and then 
placed in 24-well-plates. 
2.2.3.2. SEM of Empty Porous PLGA Scaffolds 
Scaffolds were covered by sputter coater (Bal-tec SCD 005) with 5nm gold. To 
obtain scanning electron microscope (SEM) images, samples were viewed using a 
Carl Zeiss EVO 40 Scanning Electron Microscope operated at 10.00 kV accelerating.  
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2.2.3.3. Determination of Porosity of Empty Porous  PLGA Scaffolds 
Average pore size and the pore distribution of  the porous PLGA scaffolds were 
examined using the Scion Image Analysis Program (National Institudes of Health 
(NIH) image) which is a public domain image processing and analysis program for 
the Macintosh. 
2.2.3.4.  Degradation  Study of Empty Porous PLGA Scaffolds 
For the degradation study,  PLGA scaffolds were weighed. The disks were put into 
50 mL Corning flasks containing phosphate buffer (20 mL, pH 7.4, 10 mM, 0.09% 
sodium azide) and incubated at 37 oC for 1, 15, 30, 60 and 120 days. Samples of 
solution from each foam were collected at different time points. At the end of the 
period,  the disks were freeze-dried for 8 h and weighed. At the same time, the pH in 
the supernatant (phosphate buffer) was recorded. All measurements were expressed 
as means  standard deviation (sd) relative to the initial values. This experiment was 
performed in dublicate. 
2.2.3.5. Preparation of Cell Containing Porous PLGA Scaffolds 
Porous PLGA Scaffolds were prepared as described in section 2.2.3.1. They were put 
into 24 well plates and 500 μL of 70% ice-cold ethanol was added onto each well. 
The plates were kept in 40C for 1 h for sterilization. Then, the plates were washed 
with cell culture media to remove ethanol. At the end of washing, the scaffolds were 
air dried under the laminar flow cabinet. Chondroitin sulfate (CS) (250 μL of 1%) 
was added onto each well and its saturation in the scaffolds was obtained by vacuum 
(BioVac225 Suction Systems) at 40 cm/Hg, 30 seconds for three times. After 
removing the excess solution from the wells, vacuum was applied for 30 seconds 
once more.  
 
 
Figure 2.3. Illustration of cell seeding onto porous PLGA sponges. 
Then, different nanosphere combinations such as empty PLGA nanospheres (EP), 
empty NIPAM nanospheres (EN), IGF loaded PLGA nanospheres (IP), TGF-β1 
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loaded NIPAM nanospheres (TN), IGF loaded PLGA nanospheres and IGF loaded 
NIPAM nanospheres both (IPTN) were added onto the PLGA scaffolds as presented 
in Table 2.3. After the application of vacuum for 30 seconds, seven different samples 
(with and without chondroitin sulphate controls and five different nanosphere 
content) were ready for cell seeding. 
Table. 2.3. Cell seeded  PLGA Sponges with different contents. 
 
In the next step, the cells were detached from the culture dishes and counted with C-
reader automatic cell counter (INCYTO, CRM-350). Each scaffold was seeded with 
25.000 cells/cm2 and vacuum was applied for 30 seconds again. Afterwards, the 
plates were incubated for 2 h at 370C, 5% CO2. When the cells attached to the PLGA 
scaffolds, 2% alginic acid (500 μL) was added onto each well and vacuum was 
applied for 30 seconds for once. The scaffolds were washed with PBS once and 1 mL 
cartilage differentiation medium (DMEM-high glucose with 100 unit/mL penicillin-
streptomycin, 6.25 μg/mL insulin, 6.25 μg/mL transferrin, 6.25 μg/mL selenic acid, 
5.33 μg/mL linoleic acid, 40 μg/mL proline, 100 μg Na-pyruvate, 1.25 mg/mL BSA, 
50 μg/mL L-ascorbic acid ve 100 nM dexamethasone) was added onto each well and 
then the plates were incubated into CO2 incubator at 370C. 
2.2.3.6.  Cell Growth on Cell Containing Porous PLGA Scaffolds 
CellTiter 96® AQueous One Solution Cell Proliferation Assay was used to 
determine the cell density inside the polymer scaffolds. The experiment was 
performed in triplicate at days 1, 7 and 14 after seeding the scaffolds with cells. 
DMEM low glucose medium was mixed with MTS one solution with a ratio 5:1. Cell 
seeded PLGA scaffolds were transferred into a new, sterile 24-well plate and washed 
with PBS in order to remove any left over medium. MTS- medium mix (500 μL) was 
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added onto each sample in 24-well plate and incubated for 4 h at 37ºC in a CO2 
incubator. After 4 h of incubation, 200 μL of solution from each well was transferred 
into a new 96-well plate in triplicate. Absorbance was determined at 490 nm using an 
Elisa Plate Reader (Bio-Tek, Elx800, USA).  
2.2.3.7. SEM of Cell Containing Porous PLGA Scaffolds 
At the end of 1, 7 and 14 days of incubation, SEM samples were washed with 
cacodylate buffer for three times and to fix the cells they waited in 2,5% 
gluteraldehyde for one hour and washed with Cacodylate Buffer (0.1 M, pH 7.4) for 
three times. They were washed and refrigerated in 0.1 M of sodium cacodylate buffer 
(pH 7.4) until processed for SEM. Before use, they were rinsed with deionized water 
and stored in a deep freezer (-80 oC). Before SEM observation, samples were freeze-
dried for 8h and coated with gold by sputter coater (Bal-tec SCD 005). SEM was 
carried out in a Carl Zeiss EVO 40 Scanning Electron Microscope operated at 10.00 
kV accelerating.  
2.2.3.8. Confocal Microscopy with Collagen Type II and Aggrecan Double 
Staining of Cell Containing Porous PLGA Scaffolds 
The samples were prepared as it was described in section 2.2.3.6. At the end of 1, 7 
and 14 days of incubation, they were washed with PBS for three times and waited in 
3% FBS/PBS for 10min. Collagen Type II  primary Ab was prepared in 1.5% 
FBS/PBS (1:100). The serum was extracted from the samples by pipetting and Ab 
solution was added onto each samples before washing step. The primers were 
incubated at the room temperature for 1-18 h. After the incubation, the samples were 
washed with PBS for three times and every time the samples were waited for 5 min. 
Collagen type II secondary Ab (FITC) was prepared in 1% FBS/PBS (1:200). After 
washing steps, secondary Ab solution was added onto each samples and they were 
incubated at 370C for 45 min. After the incubation, the samples were washed with 
PBS for three times and every time the samples were waited for 5 min. Another 
primary Ab, Aggrecan, was prepared in 1.5% FBS/PBS (1:200). After the washing 
steps, Aggrecan Ab solution was added onto each sample and they were incubated at 
the room temperature for 1-18 h. After the incubation, the samples were washed with 
PBS for three times and every time the samples were waited for 5 min. Secondary 
Aggrecan Ab was prepared in 1% FBS/PBS (1:200). After the washing steps,  
secondary aggrecan Ab solution was added onto each sample and they were 
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incubated at 370C for 45 min. After the incubation, the samples were washed with 
PBS for three times and they were mounted by 80-100 µL mounting medium.  
2.2.3.9. sGAG Production on Cell Containing Porous PLGA Scaffolds 
sGAG  production  of the cells in the matrix were analysed by Alcian Blue staining 
kit (pH 2,5).  Samples (described in section 2.2.3.6) were washed with dH2O and 10 
drops of reagent A was put onto them. After waiting for 30 minutes, the solution was 
drained and 10 drops of reagent B was added onto them. At the end of 10 min. of 
incubation, the samples were washed with dH2O and 10 drops of reagent C were 
added. After washing with dH2O, samples were examined under inverted 
microscope. 
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3. RESULTS 
3.1. Isolation of MSCs from Bone Marrow and Articular Cartilage Cells 
MSCs from bone marrow of the rat femur and tibia and articular cartilage cells from 
rat knee joint cartilage were isolated as described in sections 2.2.1.1 and 2.2.1.5, 
respectively.  Their morphologies were determined under the light microscope. 
Fibroblastic morphologies of the cells were observed (Figure 3.1).  
  
    
 
Figure 3.1. Monolayer growth of (a) bone marrow derived MSCs and (b) articular 
cartilage cells (x4). 
3.2. In vitro Characterization of Growth Factor Loaded Nanospheres 
3.2.1. SEM  
The surface characteristics of pH sensitive PLGA and temperature sensitive NIPAM 
nanospheres were determined by SEM.  
SEM micrographs show that both pH sensitive PLGA nanospheres and temperature 
sensitive NIPAM nanoparticles were less than 1 μm in diameter and had spheroid 
shapes (Figure 3.2).  
 
a b 
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Figure 3.2. SEM of (a) pH sensitive PLGA nanospheres and (b) temperature 
sensitive NIPAM nanospheres. 
3.2.2. Determination of Cell Growth - Calibration Curve 
The calibration curve is presented in Appendix - A1. 
3.2.3. Determination of Cell Growth in Nanosphere Containing Medium 
At the end of 1, 7 and 14 days of incubation in different culture medium (Table 3.1) 
proliferation of bone marrow derived mesenchymal stem cells were measured by 
MTS assay.  
Table 3.1. Abbreviations of the different culture mediums. 
Abbreviation Culture Medium 
OC only differentiation medium 
EP differentiation medium with empty PLGA nanospheres 
EN differentiation medium with empty NIPAM nanospheres 
IP differentiation medium with IGF-I loaded PLGA nanospheres 
TN differentiation medium with TGF-β1 loaded NIPAM 
nanospheres 
IPTN differentiation medium with IGF-I loaded PLGA nanospheres + 
TGF-β1 loaded NIPAM nanospheres 
Initial cell number was 10.000 cells/well for the cells on TCPS. The cell numbers in 
OC increased throughout the 14 days of incubation (Figure 3.4). Cells with IP, TN, 
and IPTN showed similar growth patterns with OC. However, the growth rate of 
cells with EP and EN (50.000 and 68.000 cells/well, respectively) decreased 
drastically after 14 days in culture. Cell growth in IPTN was found to be between IP 
and TN in 7 and 14 days of incubation. 
a b 
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Figure 3.3. Cell growth determination in different culture medium throughout 14 
days of incubation by MTS assay. 
At the end of 1 day of incubation, all the cells with OC, EP, EN, IP, TN and IPTN 
showed approximately same cell numbers (around 10.000-20.000 cells/well). After 7 
days in culture condition, there was a significant increase in the cell numbers in all 
the samples. Moreover, cell numbers in both EN and TN wells (around 100.000 and 
95.000 cells/well, respectively) were observed to be higher than the others. At the 
end of 14 days of incubation, however, maximum number of cells was observed in 
cells with TN and IPTN (120.000 and 105.000 cells/well, respectively). Standard 
deviations of cells with EP and EN showed the highest scores. 
3.2.4. Real Time-PCR 
Collagen Type II expression of cells with different culture medium at the end of 1, 7 
and 14 days of incubation was determined by relative Real Time PCR. 
Real Time PCR analysis showed that Collagen Type II expression of cells in OC was 
increased throughout 14 days of incubation (Figure 3.4). Cells with IP showed 
similar expression pattern with OC. However, collagen expression of cells with EN 
and IPTN decreased after 14 days in culture.   
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Figure 3.4. Collagen Type II expression of cells with different culture media at the 
end of 1, 7 and 14 days of incubation by relative Real Time PCR.  
At the end of 1 day of incubation, all the cells with EP, EN, IP, TN and IPTN except 
OC showed minimal expression levels of Collagen Type II. After 7 days in culture 
condition, there was an increase in collagen expression in cells with OC, EN, IP, and 
TN. However, it was decreased in cells with EN and IPTN. On the other hand, 
highest expression was observed in cells with OC and IP at the end of 14 days of 
incubation.  
3.2.5. Determination of ECM storage in Cell Culture Biochemical Methods - 
DMMB assay 
sGAG formation of cells with different culture medium at the end of 1, 7 and 14 days 
of incubation was determined by DMMB assay. 
DMMB assay showed that sGAG formation of cells in OC, EN, TN, and IPTN was 
increased throughout 14 days of incubation (Figure 3.5). However, it was decreased 
in cells with EP and IP after 14 days in culture.   
At the end of 1 day of incubation, all of the samples showed minimal sGAG 
formation. After 7 days in culture, there was an increase in sGAG formation in cells 
with OC, EN, IP, and IPTN. However, it was decreased in cells with TN and the 
same in cells with EP. On the other hand, highest formation was observed in cells 
with TN at the end of 14 days of incubation. Formation of sGAG was higher in cells 
with TN and IPTN than OC. 
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Figure 3.5. sGAG formation of cells with different culture medium at the end of 1, 7 
and 14 days of incubation by DMMB assay. 
3.2.6. Determination of ECM Storage in Cell Culture by Biochemical Methods-
Hydroxyproline Assay 
Collagen formation of cells with different culture medium at the end of 1, 7 and 14 
days of incubation was determined by hydroxyproline assay. 
Hydroxyproline assay demonstrated that collagen formation of cells in OC and IP 
was increased throughout 14 days of incubation (Figure 3.6). It was higher in cells 
with IP than with OC. However, it was decreased in the others in 14 days of culture.   
At the end of 1 day of incubation, all of the samples showed minimal collagen 
formation but cells with IP was high. After 7 days in culture, there was an increase in 
collagen formation in all samples. Still, highest result was obtained from the cells 
with IP at day 7 as well as day 14.  
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Figure 3.6. Collagen formation of cells in different culture media at the end of 1, 7 
and 14 days of incubation as determined by hydroxyproline assay. 
3.2.7. Determination of Cell Morphology in Cell Culture by 
Immunohistochemical Methods-Alexa Fluor® 546 Phalloidin and TO-PRO®-3 
Staining for Confocal Microscopy 
Cell morphology of cells incubated in  different culture media at the end of 7 and 14 
days of incubation was studied by confocal microscopy.  
At the end of 7 days of incubation, especially cells in IPTN expressed chondrocyte 
morphology (Figure 3.7). 
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Figure 3.7. Cell morphology of cells in different culture media at the end of 7 days 
of incubation, obtained  by confocal microscopy. (a) OC, (b) IP, (c) TN, 
and (d) IPTN. TO-PRO (blue), Phalloidin (red) (63X). 
At the end of 14 days of incubation, cellular morphology did not change for the cells 
with OC, IP, TN and IPTN. (Figure 3.8).  
 
a b 
c d 
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Figure 3.8. Cell morphology of cells in different culture media at the end of 14 days 
of incubation, as observed  by confocal microscopy. (a) OC, (b) IP, (c) 
TN, and (d) IPTN. TO-PRO (blue), Phalloidin (red) (63X). 
3.2.8. Determination of ECM Storage in Cell Culture by Immunohistochemical 
Methods-Collagen Type II and Aggrecan Confocal Microscopy Double Staining 
ECM storage of cells with different culture medium at the end of 7 and 14 days of 
incubation was determined by collagen type II and aggrecan confocal microscopy 
double staining.  
Articular cartilage was used as the positive control (Figure 3.9). At the end of 7 days 
of incubation, cells with OC demonstrated minimal ECM deposition. The cells with 
IP, TN and IPTN exhibited more ECM deposition (Figure 3.10). 
a 
c 
b 
d 
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Figure 3.9. Collagen type II and aggrecan double staining of articular cartilage on 
Day 7       (a) collagen type II (green) and aggrecan (red) (b) aggrecan 
(red) (63X). 
   
Figure 3.10. ECM storage of cells in different culture media at the end of 7 days of 
incubation  by collagen type II and aggrecan double staining of  (a) OC, 
(b) TN, and (c) IPTN. Collagen type II (green), aggrecan (red) (63X). 
At the end of 14 days of incubation, ECM content of all cells with OC, IP, TN and 
IPTN was increased in comparison to that of day 7 (Figure 3.11). ECM storage was 
still higher in cells with IP, TN and IPTN than that of OC.  
    
Figure 3.11. ECM storage of cells with different culture medium at the end of 14 
days of incubation  by collagen type II and aggrecan double staining of  
(a) OC, (b) TN, and (c) IPTN. Collagen type II (green), aggrecan (red) 
(63X). 
 
a b 
a b c 
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3.3. in situ and in vitro Characterization of PLGA Sponge Scaffolds and Growth 
Factor Loaded Nanospheres with PLGA Sponge Scaffolds 
3.3.1. SEM of Empty Porous PLGA Scaffolds 
The surface characteristics, average pore sizes and the pore distribution of the PLGA 
scaffolds were observed by SEM (Figure 3.12). By means of salt leaching method, 
the PLGA scaffolds were made porous. After salt leaching, the number of the pores 
inside the foams increased. In this study, salt crystals with a size range of 300-500 
μm were used. It was observed from the micrograph that pores were homogenously 
distributed and their sizes were between 300-500 μm. 
 
Figure 3.12. SEM of empty porous PLGA scaffolds prepared with 300-500 μm NaCl 
crystals. 
3.3.2. Porosity 
Image analysis was carried out to characterize the constructs in terms of their 
porosity. More specifically the aim was to calculate the average pore size and the 
pore size distribution of the matrices. They were examined by using Quantachrome 
Poremaster for Windows Version 4.03.  
Image analysis results showed that the porosity of the PLGA scaffolds was around 
0.521. Their pore size distributions were homogeneous with the same diameter.  
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3.3.3. Degradation Study of Empty Porous PLGA Scaffolds 
For the degradation study, empty porous PLGA foams were used. All measurements 
were expressed as means ± standard deviation (sd) relative to the initial values.  
PLGA foams led to a pH decrease of 4.9 pH units in 120 days (Figure 3.13). At the 
end of 40 days of incubation more than 90% of the PLGA foams were degraded.  
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Figure 3.13. Degradation of PLGA scaffolds by change in pH. 
3.3.4. Cell Growth on Cell Containing Porous PLGA Scaffolds 
At the end of 1, 7 and 14 days of incubation in different culture media (Table 3.2) 
proliferation of bone marrow derived mesenchymal stem cells on PLGA scaffolds 
were measured by MTS assay.  
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Table 3.2. Abbreviations of the different culture media used on PLGA scaffolds. 
Abbreviation Culture Medium 
OC only differentiation medium 
CHA chondroitin sulphate + alginate 
EP chondroitin sulphate + alginate + differentiation medium with 
empty PLGA nanospheres 
EN chondroitin sulphate + alginate + differentiation medium with 
empty NIPAM nanospheres 
IP chondroitin sulphate + alginate + differentiation medium with 
IGF-I loaded PLGA nanospheres 
TN chondroitin sulphate + alginate + differentiation medium with 
TGF- β1 loaded NIPAM nanospheres 
IPTN chondroitin sulphate + alginate + differentiation medium with 
IGF-I loaded PLGA nanospheres + TGF- β1 loaded NIPAM 
nanospheres 
The cell numbers in OC increased throughout 14 days of incubation (Figure 3.14). 
However, the amount of cells on CHA, EP, EN and IP (15.000, 25.000, 18.000 and 
20.000 cells/well, respectively) first increased until the 7 days of incubation, then, 
abrupt decrease was observed in those samples at the end of 14 days in culture. Cell 
growth in TN and IPTN was decreased throughout 14 days of incubation. 
At the end of 1 day of incubation, the cell number of all samples was lower from the 
initial cell seeding density which was 25.000 cells/well. Cells numbers of the 
samples EP and TN were higher (20.000 and 18.000 cells/well) than that of the other 
samples. After 7 days in culture, there was a significant increase in cell number in 
cells with OC, CHA, EP, EN, and IP (8.000, 15.000, 25.000, 18.000, and 20.000 
cells/well, respectively). However, it was decreased in cells with TN and IPTN 
(15.000 and 8.000 cells/well). Standard deviations of cells with EP and EN showed 
the highest scores.  
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Figure 3.14. Cell growth determination in different culture medium throughout 14 
days of incubation on PLGA scaffolds by MTS assay.  
3.3.5. SEM of Cell Containing Porous PLGA Scaffolds 
The surface characteristics and cell-surface interaction of cell seeded PLGA 
scaffolds were determined by SEM. The extent of degradation can be observed from 
the micrographs especially after 7 days of incubation 
Scanning Electron Micrographs showed the presence and attachment of the cells on 
the walls of PLGA scaffolds throughout 14 days of incubation (Figure 3.15). They 
were found in close proximity of each other due to the initial application of the cells 
on small areas on the surface of the polymers especially at the end of 1 day of 
incubation. 
   
Figure 3.15. SEM of cells with CHA on PLGA scaffolds at the end of (a) 1 day, (b) 
7 days, and (c) 14 days of incubation (400 X). 
c b a 
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Figure 3.16 shows the cells grown in different culture media on PLGA scaffolds at 
the end of 7 days of incubation. The sizes of cells were approximately 10-30 μm in 
diameter as was expected.  
                             
 
                             
Figure 3.16. Scanning Electron Micrographs of cells with different culture medium 
on PLGA scaffolds at the end of 7 days of incubation (a) CHA (400X), 
(b) IP (400X), (c) TN (400X), (d) IPTN (200X). 
3.3.6. Confocal Microscopy with Double Staining for Collagen Type II and 
Aggrecan Double Staining of Cell Containing Porous PLGA Scaffolds 
Collagen production by  cells grown in  different culture media in PLGA scaffolds at 
the end of 7 and 14 days of incubation was shown by staining for collagen type II 
and aggrecan and examining under a confocal microscope.  
Collagen production by cells grown in a medium containing IPTN increased 
gradually during the  14 days of incubation (Figure 3.17). 
c 
a b 
d 
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Figure 3.17. Collagen production by cells in PLGA scaffolds grown in IPTN 
medium at the end of (a) 1 day, (b) 7 days, and (c) 14 days of 
incubation. Staining was for collagen type II (green), aggrecan (red) 
(63X).  
At the end of 14 days of incubation, collagen formation by cells in PLGA scaffolds 
grown in OC medium was found much more than that in TN and IPTN (Figure 3.18). 
   
Figure 3.18. Collagen production by cells grown in different culture media in  PLGA 
scaffolds at the end of 14 days of incubation. Staining was for collagen 
type II and aggrecan . Media (a) OC, (b) TN, and (c) IPTN. Collagen 
type II (green), aggrecan (red) (63X). 
3.3.7. sGAG Production in Cell Loaded Containing Porous PLGA Scaffolds 
sGAG production by cells grown in  different culture medium into the PLGA 
scaffolds at the end of 1, 7 and 14 days of incubation was determined by alcian blue 
and nuclear fast red staining. 
Alcian blue stains sGAG in the cells and if there are sGAG in the medium, the color 
turns to blue. Nuclear fast red staining stains the nucleus red. This test showed that at 
the end of 1 day of incubation, nuclei of all the samples were stained red. Then, after 
7 days of incubation, blue staining was observed due to the presence of sGAG 
(Figure 3.19).   
a b c 
a b c 
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Figure 3.19. sGAG formation of cells with IP into the PLGA scaffolds as shown by 
alcian blue and nuclear fast red staining at the end of (a) 1 day, (b) 7 
days, (c) 14 days of incubation (4X). 
Figure 3.20 shows that at the end of 1 day of incubation, all of the samples were 
negative. After 7 days in culture, there was an increase in sGAG production in all the 
samples. Cells with IP and IPTN had the highest sGAG content. At the end of 14 
days of incubation, the scores in all the samples had increased. Cells with IP gave the 
best result in this test. Level of sGAG formation in IPTN was found to be between IP 
and TN after 14 days of incubation. 
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Figure 3.20. sGAG formation of cells with different culture medium into the PLGA 
scaffolds at the end of 7 and 14 days of incubation by alcian blue 
staining.   
 
a b c 
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4. DISCUSSION 
There are two major growth factors that forces cells to differentiate into 
chondrocytes, IGF-I and TGFβ-I. These growth factors were loaded in synthetic 
polymeric nanospheres that are pH sensitive PLGA and temperature sensitive 
NIPAM. In this study, mesenchymal cells (MSCs) were exposed to empty and 
growth factor loaded nanospheres both in the presence and absence of PLGA 
scaffold to provide differentiation of cells into chondrocytes. 
There are two sets of experiments in this study, in the first part of the experiment (on 
TCPS), MTS tests were carried out to determine the density of cells grown in 
different media on TCPS. In order to find the exact cell number, a calibration curve 
was constructed. Cell numbers on all samples increased by time except those grown 
in EP and EN. The decrease in cell number of EP and EN might be due to the 
presence of the nanospheres. Addition of growth factors into the nanospheres 
reverted this pattern. TGF- β has an indirect mitogenic effect for certain MSCs and is 
a stimulator of extracellular matrix deposition (Kay et al., 1998, Moses et al, 1991, 
Lee et al, 2006). Since TGFβ-1 has a mitogenic activity on cells, increase in 
proliferation can be seen in both TN and IPTN. Since the cell growth rate of IPTN 
was found between IP and TN in 7 and 14 days of incubation, it could be the 
evidence for the cumulative effect of the growth factors released at the same time. 
Moreover, cell numbers in both EN and TN wells were observed to be higher than 
the others. Also, maximum growth rate was observed in cells with TN and IPTN at 
the end of 14 days of incubation. Samples incubated with NIPAM showed higher 
cellular growth than samples incubated in PLGA.  
After observing the cell proliferation rate on TCPS, the differentiation of the cells 
was determined by real time PCR, DMMB and hydroxyproline assay and 
immunofluorescence methods. Collagen Type II is the major component of hyaline 
joint cartilage (Pulkkinen, 2008). Highest expression was observed due to 
differentiation in cells with OC and IP at the end of 14 days of incubation according 
to collagen type II expression results in real time PCR. Insulin-like growth factor I 
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(IGF-I) is known to stimulate collagen production (Olsen et al., 2007; Sonal, 2001). 
The reason why also cells with OC showed differentiation was that the medium of  
OC contains basal level of differentiation factors itself. 
In order to support real time PCR, biochemical methods were also used for 
differentiation of cells. Collagen type II is produced and then secreted by 
chondrocytes, supporting chondrocyte adhesion and phenotypic differentiation of 
cells. It contains specifically proline and lysine amino acids and many modifications 
that are almost unique to collagen. These modifications such as hydroxylation of 
residues are introduced during biosynthesis eventually creating hydroxyproline. So 
the hydroxyproline assay gives information about the collagen production and 
cartilage differentiation. This assay shows that cells with IP produced highest 
collagen at the end of 7 and 14 days. Moreover, cells with IP showed higher score 
than OC for both time points. This data confirms the real time PCR data. 
Another biochemical method was used to determine the ECM deposition is the 
measurement of sGAG formation. The test showed that sGAG formation of cells in 
OC, EN, TN, and IPTN was increased during the 14 days of incubation. ECM 
storage is important in cartilage formation.  The highest levels of sGAG formation 
were observed in cells with TN and IPTN. There are several reports demonstrating 
that TGF-β1 supports the aggrecan deposition by regulation of aggrecanase inhibitor. 
(Kudo et al., 2001; Yamanishi et al., 2002). Poleni et al. (2007) found that TGF-β1 
increased GAGs' content and deposition in rat cartilage cells by 3.5-fold and six-fold, 
respectively, and induced aggrecan expression around 10-fold. The amount sGAG 
production in IPTN containing medium was found to be between IP and TN in 7 and 
14 days of incubation, showing the combined effect of the two growth factors 
simultaneously. 
Cell morphology, Collagen Type II and aggregan deposition were measured by 
confocal microscopy. First, cells were stained with Alexa Fluor® 546 Phalloidin for 
actin filaments, and TO-PRO®-3 for nuclei to have information about cell 
morphology. TGFβ-1 containing cells were observed to be highly proliferative. This 
result supports the MTS assay results.   
ECM storage of cells with different culture medium at the end of 7 and 14 days of 
incubation was determined in confocal microscopy by collagen type II and aggrecan 
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double staining. In this study, articular cartilage cells were used as a positive control. 
It was observed that collagen type II was deposited around the nucleus. However, 
cells with OC did not express the same behavior. Collagen type II was distributed all 
over the cytoplasm. On the other hand, cells with IP, TN and IPTN showed similar 
accumulation patterns of collagen type II with articular cartilage cells. Moreover, 
cells with TN showed high amount of aggrecan deposition which supports the data of 
DMMB assay.  
In the second part of the study (on scaffold), first the porosity and degradation rate of 
PLGA scaffold were studied. The pore size and the pore distribution are quite 
important parameters for cell growth inside the matrices. Since cells cannot grow 
without cell to cell contact, the average size of the pores should be at least 3 times 
bigger than that of the cells so that a single cell can find a chance to establish contact 
with the others. SEM micrographs showed that pores were homogenously distributed 
and their sizes were between 200-400 μm, that are large enough for cell penetration 
and growth. Degradation study showed that at the end of 40 days of incubation, more 
than 90% of the PLGA foams were degraded. Degradation of PLGA is followed by 
pH decreases due to lactic acid release and therefore, the sample that leads to the 
largest pH drop would have been the one that has degraded the most. 
Cell growth on porous PLGA scaffolds was determined by MTS assay. During initial 
seeding, cells did not attach onto the PLGA scaffold surface properly. They might 
prefer to grow onto TCPS. The maximum cellular attachment was observed in cells 
with EP. The number of the cells with TN and IPTN decreased at day 7: Cells might 
prefer to undergo differentiation more than proliferation due to the effect of growth 
factors. Cells can not grow and differentiate at the same time. One reason of the 
decrease in the cell number of all samples except OC at the day of 14 could be due to 
the rapid degradation of the PLGA. The other reason could be the absence of 
chondroitin sulphate in cells with OC. Chondroitin sulphate is an essential 
component of cartilage tissue, so it could lead to cellular differentiation. Because of 
that reason, cell number of the other samples except OC might droped at the end of 
14 days of incubation.  
SEM was used to determine the surface characteristics and cell-surface interaction of 
the cell seeded PLGA scaffolds. From these micrographs, one can not decide which 
culture medium is ideal for the MSC differentiation into cartilage since only a small 
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fraction of the polymers were examined under the SEM. In these aspects 
immunochemical data are expected to be more conclusive.    
Collagen formation of cells in different culture medium on PLGA scaffolds at the 
end of 7 and 14 days of incubation was determined by collagen type II and aggrecan 
double staining and confocal microscopy examination. Collagen formation of cells 
with IPTN into the PLGA scaffolds was increased throughout 14 days of incubation. 
Cells seeded in PLGA scaffolds in the presence of different culture medium were 
stained with alcian blue to determine sGAG formation at 1, 7 and 14 days of 
incubation. Alcian blue stains both sulfated and carboxylated acid 
mucopolysaccharides and sulfated and carboxylated glycoproteins. The rate of alcian 
blue staining score is directly correlated with cellular differentiation into the 
cartilage. At the end of 1 day of incubation, the cell nucleuses were observed as red 
color by nuclear fast red stain. There was no blue color seen due to the fact that cells 
did not expressed sGAG component. At day 7, samples stained with alcian blue as 
was expected. The highest scores were observed by the cells with IP and IPTN at 
both day 7 and 14. The samples with CHA showed higher sGAG formation than OC 
on day 7 and 14. Moreover, there was no effect of cells with EP on the cellular 
sGAG formation. In the case of cells with EN, sGAG formation was lower than that 
of CHA. The reason could be the suppressive effect of EN on the expression of 
sGAG.  sGAG formation rate in IPTN was again found between IP and TN in 14 
days of incubation. 
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5. CONCLUSION 
Mimicking the structure and function of the natural ECM is one of the most 
important requirements in tissue engineering. At the end of the study, the interaction 
between cells and biodegradable nanospheres has been identified. The assays showed 
that, the release of growth factors affect both the cells on TCPS and in the scaffolds. 
Responsive nanospheres were used in the controlled release of GFs for chondrocyte-
like cell development in scaffolds. Biochemical and immunofluorescence analysis 
gave information on the success of cell differentiation. At the end of the study, it can 
be concluded that cells with IP and IPTN nanospheres give the best results with 
respect to cartilage differentiation onto scaffolds. It thus appears that, usage of 
growth factor loaded nanospheres could have a serious contribution on cartilage 
tissue engineering. In future studies, the physiological aspect of this interaction could 
also be investigated to find out the effects of these nanospheres on cells in vivo. 
Also, the responsiveness of these nanospheres needs to be tested to control the 
release of the growth factors within the scaffolds. 
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